Rocuronium bromide (1-[(2β,3α,5α,16β,17β)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)pyrrolidinium bromide) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia to facilitate tracheal intubation by providing skeletal muscle ralaxation, most commonly required for surgery or mechanical ventilation. It has antagonistic properties that target the neuromuscular nicotinic acetylcholine receptor, and has a shorter time of onset of action than vecuronium bromide.
Rocuronium: The newest aminosteroid neuromuscular blocking drug.
Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors.
Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969.
Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey.
 J.M.Hunter, et al, Br. J. Anaesth., 1996, 76, pp 481-483.
 V.Y.Hou, et al, Anesthesiology, 1998, 88(3), pp 744-750.
 O.Epemolu, et al, Anesthesiology, 2003, 99(3), pp 632-637.
 H.D.de Boer, et al, Br. J. Anaesth., 2006, 96(4), pp 473-479.